HPGC Renmintongtai Pharmaceutical Corp operates in the Drug stores and proprietary stores sector.
In addition to historical fundamental analyses, the complete report available to purchase compares HPGC Renmintongtai Pharmaceutical Corp with three other
companies in this sector in CHINA :
Yixintang Pharmaceutical Group Co Ltd
sales of 10.48 billion Chinese Renmimbi [US$1.50 billion]
of which 95%
was Retail Sale),
Dashenlin Pharmaceutical Group Co Ltd
(11.14 billion Chinese Renmimbi [US$1.60 billion]
of which 125%
was South China), and
Yifeng Pharmacy Chain Co Ltd
(10.28 billion Chinese Renmimbi [US$1.47 billion]
of which 93%
was Medicine Retail).
HPGC Renmintongtai Pharmaceutical Corp reported sales of 8.35 billion Chinese Renmimbi (US$1.20 billion)
December of 2019.
increase of 18.4%
versus 2018, when the company's sales were 7.06 billion Chinese Renmimbi.
Sales of Pharmaceutical Commerce saw an increase
18.8% in 2019, from
6.93 billion Chinese Renmimbi to 8.23 billion Chinese Renmimbi.
Not all segments of HPGC Renmintongtai Pharmaceutical Corp experienced an increase in sales in 2019:
sales of Other Operation fell 8.3% to 80.82 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).